Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
The Captial Market (CapitalMarket.com) rating for Rossari Biotech IPO is 48. Their analysis recommends May Subscribe for the IPO.
| Reviewer | Rating Score | Rating |
|---|---|---|
| Capital Market | 48 | May Subscribe |
[Dilip Davda] On the current parameters, the issue appears fully priced. However, considering bright prospects going forward with more than double installed capacity and rising patronage by top clients with long term relations, investors may consider investment for long term rewards. Read detail review...
Rossari Biotech IPO Reviews, analysis and views by popular members. Read Rossari Biotech Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
RHP